|
Market Closed -
Canadian Securities Exchange
14:35:17 12/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.0100 CAD | 0.00% |
|
+100.00% | -33.33% |
| 05-28 | Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-30 | Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.34M 967K 835K 785K 714K 92.48M 1.36M 9.2M 3.6M 46.31M 3.63M 3.55M 154M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.84M 2.05M 1.77M 1.66M 1.51M 196M 2.89M 19.48M 7.62M 98.1M 7.69M 7.52M 326M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | +100.00% | ||
| 3 months | -33.33% | ||
| Current year | -33.33% |
| 1 week | 0.01 |  | 0.01 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 19/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 19/12/2016 |
David Kideckel
CHM | Chairman | - | 26/02/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/10/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 03/05/24 | Other | Director | 0 | 0% | ||
| 03/05/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +100.00% | 0.00% | -85.71% | 967K | |
| +1.44% | -0.07% | +29.11% | +102.27% | 101B | |
| +1.70% | -0.52% | +57.19% | +160.14% | 54.69B | |
| -1.01% | -0.34% | +3.15% | +288.16% | 24.3B | |
| -1.13% | -0.66% | -11.80% | -15.49% | 8.24B | |
| +0.54% | +2.52% | -30.90% | -24.07% | 7.73B | |
| +0.96% | -1.17% | -12.91% | -20.85% | 6.64B | |
| +0.82% | +2.69% | +10.68% | +17.57% | 6.33B | |
| -0.09% | -1.64% | -3.64% | +15.42% | 4.98B | |
| -0.59% | +1.40% | -5.24% | -7.41% | 3.74B | |
| Average | +0.26% | -0.15% | +3.56% | +43.00% | 21.8B | |
| Weighted average by Cap. | +1.00% | -0.19% | +26.44% | +118.51% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -572K -494K -464K -422K -54.66M -806K -5.44M -2.13M -27.37M -2.15M -2.1M -90.96M | -383K -276K -239K -224K -204K -26.42M -390K -2.63M -1.03M -13.23M -1.04M -1.01M -43.96M |
| Net Debt | 1.27M 918K 793K 745K 678K 87.78M 1.29M 8.73M 3.41M 43.96M 3.45M 3.37M 146M | 1.5M 1.08M 934K 878K 798K 103M 1.53M 10.29M 4.02M 51.79M 4.06M 3.97M 172M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/08/26 | CA$0.0100 | 0.00% | 93,100 |
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
